[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Illumina Inc (ILMN)

Illumina Inc (ILMN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Illumina Reports Tomorrow With Analysts Already Comfortable at Five Dollars Per Share

Illumina Inc. (NASDAQ: ILMN) reports second quarter 2026 earnings after market close on Thursday, July 30, 2026, with analysts expecting $1.23 per share on revenue of approximately $1.13 billion. The genomics sequencing leader faces a critical test as investors weigh whether its recent momentum can continue amid questions about demand trends in its core markets and the sustainability of its margin expansion. With the stock up sharply from its lows and trading above all major moving averages, the setup heading into this release reflects heightened expectations for execution.

Illumina develops, manufactures, and markets life science tools and integrated systems for large-scale analysis of genetic variation...

Fundamentals

See More
  • Market Capitalization, $K 29,476,268
  • Shares Outstanding, K 151,300
  • Annual Sales, $ 4,343 M
  • Annual Income, $ 850,000 K
  • EBIT $ 862 M
  • EBITDA $ 1,132 M
  • 60-Month Beta 1.47
  • Price/Sales 6.72
  • Price/Cash Flow 28.74
  • Price/Book 10.91

Options Overview Details

View History
  • Implied Volatility 56.43% (-1.79%)
  • Historical Volatility 38.31%
  • IV Percentile 93%
  • IV Rank 75.37%
  • IV High 63.56% on 10/30/25
  • IV Low 34.59% on 11/14/25
  • Expected Move (DTE 22) 19.59 (9.78%)
  • Put/Call Vol Ratio 0.61
  • Today's Volume 1,247
  • Volume Avg (30-Day) 626
  • Put/Call OI Ratio 0.39
  • Today's Open Interest 15,026
  • Open Int (30-Day) 15,763
  • Expected Range 180.72 to 219.90

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $1.23
  • Number of Estimates 5
  • High Estimate $1.26
  • Low Estimate $1.21
  • Prior Year $1.19
  • Growth Rate Est. (year over year) +3.36%

Price Performance

See More
Period Period Low Period High Performance
1-Month
175.60 +14.69%
on 07/01/26
201.68 -0.14%
on 07/30/26
+25.56 (+14.54%)
since 06/30/26
3-Month
128.06 +57.26%
on 05/01/26
201.68 -0.14%
on 07/30/26
+74.65 (+58.90%)
since 04/30/26
52-Week
88.00 +128.85%
on 10/14/25
201.68 -0.14%
on 07/30/26
+94.73 (+88.81%)
since 07/30/25

Most Recent Stories

More News
Illumina Reports Tomorrow With Analysts Already Comfortable at Five Dollars Per Share

Barchart Research What to Expect from ILMN Earnings ILMN Generated July 29, 2026 Current Price $194.82 EPS Estimate $$1.23 Consensus Rating Moderate Buy Average Move 8.69% Illumina Reports Tomorrow With...

ILMN : 203.66 (+4.54%)
Illumina Earnings: What To Look For From ILMN

Illumina Earnings: What To Look For From ILMN

ILMN : 203.66 (+4.54%)
3 Healthcare Stocks with Questionable Fundamentals

3 Healthcare Stocks with Questionable Fundamentals

TNDM : 18.49 (-0.54%)
ILMN : 203.66 (+4.54%)
HAE : 84.25 (-1.37%)
3 Profitable Stocks We Find Risky

3 Profitable Stocks We Find Risky

VFC : 14.84 (-1.59%)
ILMN : 203.66 (+4.54%)
SBGI : 13.74 (-3.24%)
Illumina expands Billion Cell Atlas program with new AI drug developers

Partners will use unprecedented data scale to advance more precise medicines to approval

ILMN : 203.66 (+4.54%)
Illumina to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026

SAN DIEGO , July 9, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today that it will issue results for the second quarter 2026 following the close of market on Thursday, July 30, 2026....

ILMN : 203.66 (+4.54%)
Illumina appoints Michael Sullivan Chief Commercial Officer and Julie Coletti Chief Legal Officer

New leaders bring extensive leadership experience across life sciences, diagnostics, and medical technology

ILMN : 203.66 (+4.54%)
2 Mooning Stocks Worth Investigating and 1 We Avoid

2 Mooning Stocks Worth Investigating and 1 We Avoid

HLF : 12.41 (-0.80%)
ILMN : 203.66 (+4.54%)
EAT : 207.94 (+1.07%)
Life Sciences Tools & Services Stocks Q1 Results: Benchmarking Illumina (NASDAQ:ILMN)

Life Sciences Tools & Services Stocks Q1 Results: Benchmarking Illumina (NASDAQ:ILMN)

ILMN : 203.66 (+4.54%)
1 High-Flying Stock with Solid Fundamentals and 2 We Find Risky

1 High-Flying Stock with Solid Fundamentals and 2 We Find Risky

VTS : 15.21 (-1.55%)
ILMN : 203.66 (+4.54%)
LBRT : 18.05 (+5.62%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Illumina Inc. is a life sciences company, which provides tools and integrated systems for analysis of genetic variation and function. Using its proprietary technologies, the company provides innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies,...

See More

Key Turning Points

3rd Resistance Point 205.05
2nd Resistance Point 200.87
1st Resistance Point 197.84
Last Price 203.66
1st Support Level 190.63
2nd Support Level 186.45
3rd Support Level 183.42

See More

Last Price 203.66
52-Week High 201.68
Fibonacci 61.8% 158.25
Fibonacci 50% 144.84
Fibonacci 38.2% 131.43
52-Week Low 88.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.